Calla Lily Clinical Care has secured a £700k Innovate UK grant to adapt its intravaginal drug delivery platform for live biotherapeutics and probiotics targeting vaginal microbiome health.

The funding will support a £1 million project, named FLORA (Focused Lactobacillus Optimised Retention and Adhesion), which aims to optimise the delivery, transfer and retention of beneficial Lactobacillus species to help restore vaginal microbiome health.
The programme will focus on vaginal dysbiosis, including bacterial vaginosis (BV), for which treatment remains largely antibiotic-based despite high recurrence rates. BV recurs in approximately 58 percent of women within 12 months, contributing to the wider challenge of antimicrobial resistance (AMR).
Calla Lily aims to develop Callavid® as an over-the-counter product designed to improve probiotic transfer, retention and colonisation, addressing limitations associated with existing treatment formats, including leakage and inconsistent dosing. The project will also establish a laboratory model to assess bacterial colonisation and inform future product development.
The award represents the third Innovate UK grant secured by Calla Lily Clinical Care, further strengthening its portfolio of women’s health innovations. The company’s other programmes include an NIHR-funded clinical trial evaluating progesterone delivery via Callavid in patients with luteal phase insufficiency, and participation in Wellcome Leap’s $50 million Focused Antibiotics programme, which aims to improve antibiotic delivery and address antimicrobial resistance.
“In under two years, the Callavid platform has won competitive funding for three different therapies: progesterone, antibiotics, and now live biotherapeutics and probiotics,” said Thang Vo-Ta, Co-Founder and CEO of Calla Lily Clinical Care.
“The vaginal microbiome is one of the most exciting frontiers in women’s health, but even the best bacteria will only help if they reach the right place and stay there.”



No comments yet